{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:50:07Z","timestamp":1772578207683,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T00:00:00Z","timestamp":1277337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10549-010-0981-1","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T05:10:14Z","timestamp":1277269814000},"page":"767-779","source":"Crossref","is-referenced-by-count":57,"title":["Prognostic factors for skeletal complications from metastatic bone disease in breast cancer"],"prefix":"10.1007","volume":"123","author":[{"given":"Janet E.","family":"Brown","sequence":"first","affiliation":[]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,6,24]]},"reference":[{"key":"981_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"issue":"Suppl","key":"981_CR2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(Suppl):1588\u20131594","journal-title":"Cancer"},{"key":"981_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/SCT.2005.n.017","volume":"2","author":"PP Major","year":"2005","unstructured":"Major PP, Cook RJ, Chen BL et al (2005) Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2:234\u2013240","journal-title":"Support Cancer Ther"},{"key":"981_CR4","first-page":"341","volume":"4","author":"T Delea","year":"2006","unstructured":"Delea T, McKiernan J, Brandman J et al (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4:341\u2013347","journal-title":"J Support Oncol"},{"key":"981_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"981_CR6","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925\u20134935","journal-title":"J Clin Oncol"},{"key":"981_CR7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"981_CR8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"981_CR9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"981_CR10","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150\u20133157","journal-title":"J Clin Oncol"},{"key":"981_CR11","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621","journal-title":"Cancer"},{"key":"981_CR12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031\u20132037","journal-title":"Br J Cancer"},{"key":"981_CR13","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","volume":"34","author":"A Lipton","year":"1998","unstructured":"Lipton A, Demers L, Curley E et al (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021\u20132026","journal-title":"Eur J Cancer"},{"key":"981_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","volume":"113","author":"A Lipton","year":"2008","unstructured":"Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193\u2013201","journal-title":"Cancer"},{"key":"981_CR15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3928\/0147-7447-20010601-25","volume":"24","author":"B Patel","year":"2001","unstructured":"Patel B, DeGroot H (2001) Evaluation of the risk of pathologic fractures secondary to metastatic bone disease. Orthopedics 24:612\u2013617 quiz 618-619","journal-title":"Orthopedics"},{"key":"981_CR16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","volume":"9","author":"PP Major","year":"2009","unstructured":"Major PP, Cook RJ, Lipton A et al (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272","journal-title":"BMC Cancer"},{"key":"981_CR17","doi-asserted-by":"crossref","unstructured":"Kaminski M, Rosen LS, Gordon D et al (2005) Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications [poster]. Presented at primary therapy of early breast cancer 9th international conference; 26\u201329 January, 2005; St. Gallen, Switzerland. Abstract 107","DOI":"10.1016\/S0960-9776(05)80143-2"},{"key":"981_CR18","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"981_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36\u201343","journal-title":"Cancer"},{"key":"981_CR20","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data. Wiley, New York, NY"},{"key":"981_CR21","volume-title":"Statistical models and methods for lifetime data","author":"JF Lawless","year":"2003","unstructured":"Lawless JF (2003) Statistical models and methods for lifetime data. Wiley, Hoboken, NJ"},{"key":"981_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2753.2001.00262.x","volume":"7","author":"MB Barton","year":"2001","unstructured":"Barton MB, Dawson R, Jacob S et al (2001) Palliative radiotherapy of bone metastases: an evaluation of outcome measures. J Eval Clin Pract 7:47\u201364","journal-title":"J Eval Clin Pract"},{"key":"981_CR23","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"981_CR24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2008.03.082","volume":"34","author":"RE Coleman","year":"2008","unstructured":"Coleman RE, Brown J, Cook R (2008) Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: multivariate analysis in women with metastatic breast cancer (BC). Cancer Treat Rev 34(Suppl 1):28\u201329 Abstract P61","journal-title":"Cancer Treat Rev"},{"key":"981_CR25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11914-008-0027-3","volume":"6","author":"RD Jackson","year":"2008","unstructured":"Jackson RD, Donepudi S, Mysiw WJ (2008) Epidemiology of fracture risk in the women\u2019s health initiative. Curr Osteoporos Rep 6:155\u2013161","journal-title":"Curr Osteoporos Rep"},{"key":"981_CR26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744","journal-title":"Cancer"},{"key":"981_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","volume":"12","author":"A Lipton","year":"2007","unstructured":"Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035\u20131043","journal-title":"Oncologist"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0981-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-0981-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0981-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:39:13Z","timestamp":1635554353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-0981-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,24]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-0981-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,24]]}}}